Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis

Arthritis Rheum. 2007 Jun;56(6):1836-45. doi: 10.1002/art.22714.

Abstract

Objective: Stimulation of invariant natural killer T (iNKT) cells with SGL-S23, a novel synthetic glycolipid analog of alpha-galactosylceramide with an elongated sphingosine chain, has been shown to strongly suppress K/BxN serum transfer arthritis. This study was designed to evaluate the protective effects of SGL-S23 in an effector phase of arthritis.

Methods: To induce arthritis, C57BL/6 mice were injected with 150 mul of serum from K/BxN mice (KRN TCR-transgenic mice crossed with nonobese diabetic mice). Subsequently, synthetic glycolipid ligands were administered intraperitoneally twice, either 3 times starting on day 0 (the day of K/BxN serum injection) or twice starting on day 3. Neutralizing antibody against interferon-gamma (IFNgamma) interleukin-4 (IL-4), IL-10, or transforming growth factor beta was administered 4 hours before injection of SGL-S23. Recombinant IFNgamma was administered subcutaneously every day. The severity of arthritis was monitored using a macroscopic scoring system. Cytokine production and plasma histamine levels were measured by enzyme-linked immunosorbent assay.

Results: SGL-S23 strongly suppressed K/BxN serum transfer arthritis by inhibiting inflammatory cell infiltration and subsequent destruction of cartilage and bone. The inhibitory effect mediated by SGL-S23 was abolished by neutralization of IFNgamma. Systemic administration of IFNgamma prevented the development of inflammatory arthritis. Histamine release was suppressed by administration of SGL-S23 or IFNgamma. Degranulated mast cells in the synovium were significantly reduced in SGL-S23-treated mice, suggesting that suppression of mast cell activation contributed to the inhibition of arthritis.

Conclusion: These findings suggest that activation of iNKT cells with glycolipid ligands holds promise with regard to the treatment of autoimmune diseases such as rheumatoid arthritis. SGL-S23 has clinical benefit over alpha-galactosylceramide since it induces a weaker cytokine production response in iNKT cells, therefore reducing potential side effects caused by excessive cytokine release.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Arthritis, Experimental / immunology*
  • Arthritis, Experimental / pathology
  • Arthritis, Experimental / prevention & control*
  • Autoantibodies / immunology
  • Cytokines / metabolism
  • Galactosylceramides / pharmacology*
  • Glycolipids / pharmacology*
  • Histamine / metabolism
  • Interferon-gamma / pharmacology
  • Killer Cells, Natural / drug effects*
  • Killer Cells, Natural / immunology*
  • Ligands
  • Mast Cells / drug effects
  • Mast Cells / metabolism
  • Mast Cells / pathology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic

Substances

  • Adjuvants, Immunologic
  • Autoantibodies
  • Cytokines
  • Galactosylceramides
  • Glycolipids
  • Ligands
  • alpha-galactosylceramide
  • suppressor glycolipid S23
  • Histamine
  • Interferon-gamma